This is not the most recent version of the article. View current version (17 JUL 2015)

Intervention Protocol

You have free access to this content

Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)

  1. Féline PB Kroon1,*,
  2. Lennart RA van der Burg1,
  3. Sofia Ramiro2,
  4. Robert BM Landewé2,3,
  5. Rachelle Buchbinder4,
  6. Désirée van der Heijde1

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 30 JAN 2014

DOI: 10.1002/14651858.CD010952


How to Cite

Kroon FPB, van der Burg LRA, Ramiro S, Landewé RBM, Buchbinder R, van der Heijde D. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010952. DOI: 10.1002/14651858.CD010952.

Author Information

  1. 1

    Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands

  2. 2

    Academic Medical Center, University of Amsterdam, Department of Clinical Immunology and Rheumatology, Amsterdam, Netherlands

  3. 3

    Atrium Medical Centre, Department of Rheumatology, Herleen, Netherlands

  4. 4

    Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Monash Department of Clinical Epidemiology, Cabrini Hospital, Malvern, Victoria, Australia

*Féline PB Kroon, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands. felinekroon@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 JAN 2014

SEARCH

This is not the most recent version of the article. View current version (17 JUL 2015)

References

Additional references

Amor 1990
  • Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. Revue du rhumatisme et des maladies osteo-articulaires 1990;57:85-9.
Anderson 2001
Armstrong 1987
Bertolini 2002
Bhala 2013
  • Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79.
Bombardier 2000
  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine 2000;343:1520-8.
Brandt 2004
  • Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Annals of the Rheumatic Diseases 2004;63:1438-44.
Braun 2007
Braun 2011
  • Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargoas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 2011;70:896-904.
Calin 1994
  • Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. Journal of Rheumatology 1994;21:2281-5.
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Dougados 1991
Dougados 1995
Doward 2003
  • Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Annals of the Rheumatic Diseases 2003;62:20-6.
Feenstra 2002
  • Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Archives of Internal Medicine 2002;162:265-70.
Fries 1991
  • Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. Journal of Rheumatology Supplement 1991;28:6-10.
Gabriel 1991
  • Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Annals of Internal Medicine 1991;115:787-96.
Garrett 1994
  • Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. Journal of Rheumatology 1994;21:2286-91.
GRADE Working Group 2004
Griffin 1988
Hayden 2006
Higgins 2011a
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011b
  • Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Higgins 2011c
  • Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Jenkinson 1994
  • Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. Journal of Rheumatology 1994;21:1694-8.
Kearney 2006
  • Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
Khan 1985
Khan 1990
Langman 1994
Lefebvre 2011
  • Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
MacDonald 1997
  • MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchirst MM, Murray FE. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315:1333-7.
Machado 2010
  • Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2010;69:1465-70.
Machado 2011a
  • Machado P, Landewe R, Braun J, Hermann KG, Baraliakos X, Baker D, et al. A stratified model for health outcomes in ankylosing spondylitis. Annals of the Rheumatic Diseases 2011;70:1758-64.
Machado 2011b
  • Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Annals of the Rheumatic Diseases 2011;70:47-53.
Mau 1988
  • Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. Journal of Rheumatology 1988;15:1109-14.
Murray 1993
  • Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annual Review of Pharmacology and Toxicology 1993;33:435-65.
Oostveen 1999
  • Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. Journal of Rheumatology 1999;26:1953-8.
Poddubnyy 2012
  • Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases 2012;71:1616-22.
Review Manager 2013
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Rudwaleit 2004
  • Rudwaleit M, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. The burden of disease in patients with ankylosing spondylitis (AS) and pre-radiographic axial spondyloarthritis. Arthritis and Rheumatism 2004;50:S211.
Rudwaleit 2005
Rudwaleit 2009a
  • Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Annals of the Rheumatic Diseases 2009;68:770-6.
Rudwaleit 2009b
  • Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the Rheumatic Diseases 2009;68:777-83.
Said-Nahal 2000
  • Said-Nahal R, Miceli-Richard C, Berthelot JM, Duche A, Dernis-Labous E, Le Blevec G, et al. The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Francais d'Etude Genetique des Spondylarthropathies. Arthritis and Rheumatism 2000;43:1356-65.
Sampaio-Barros 2001
Schünemann 2011
  • Schünemann H, Oxman A, Higgins J, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Siegle 1998
Sieper 2009
  • Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Annals of the Rheumatic Diseases 2009;68 Suppl 2:ii1-44.
Stalnikowicz 1993
Sterne 2011
  • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Stolwijk 2012
Trelle 2011
  • Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
van der Heijde 2008a
van der Heijde 2008b
van der Heijde 2009a
  • van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2009;68:1811-8.
van der Heijde 2009b
  • van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Research & Therapy 2009;11:R127.
van der Heijde 2011
  • van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases 2011;70:905-8.
van der Linden 1984
Vane 1998
Visual Rx 2008
  • Dr Christopher Cates' EBM Web Site. Visual Rx. 3. Dr Christopher Cates' EBM Web Site, 2008.
Wanders 2004
Wanders 2005
Ware 1992
Zhang 2002
  • Zhang X, Schwarz EM, Young DA, Puzas JE, Rossier RN, O'Keefe RJ, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. Journal of Clinical Investigation 2002;109:1405-15.